Nxstage Medical (Nasdaq: NXTM) reported earnings on July 25. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Nxstage Medical beat slightly on revenues and exceeded expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded. GAAP loss per share dropped.

Gross margins grew, operating margins dropped, net margins grew.

Revenue details
 Nxstage Medical reported revenue of $65.5 million. The 12 analysts polled by S&P Capital IQ expected to see sales of $64.5 million on the same basis. GAAP reported sales were 11% higher than the prior-year quarter's $59.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at -$0.06. The 11 earnings estimates compiled by S&P Capital IQ averaged -$0.07 per share. GAAP EPS were -$0.06 for Q2 versus -$0.09 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 38.3%, 40 basis points better than the prior-year quarter. Operating margin was -6.5%, 90 basis points worse than the prior-year quarter. Net margin was -5.2%, 340 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $67.6 million. On the bottom line, the average EPS estimate is -$0.06.

Next year's average estimate for revenue is $266.1 million. The average EPS estimate is -$0.26.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 137 members out of 168 rating the stock outperform, and 31 members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 41 give Nxstage Medical a green thumbs-up, and eight give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nxstage Medical is outperform, with an average price target of $15.65.

Is Nxstage Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.